Company news
Shuttle Pharmaceuticals Holdings, Inc. news in 2025
Shuttle Pharmaceuticals Holdings, Inc.'s news releases, calls and decks from 2025, newest first.
Shuttle Pharmaceuticals Acquires AI Health Platform
November 21, 2025
Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00
November 3, 2025
Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ: SHPH)
October 21, 2025
Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform
October 21, 2025
Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ: SHPH)
October 20, 2025
Shuttle Executes LOI with Molecule.ai
October 10, 2025
Shuttle to Enter $3.24 Billion AI Pharmaceutical Market
October 9, 2025
Shuttle Pharma Provides Second Quarter 2025 Corporate Update
August 14, 2025
Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
June 24, 2025
Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
June 20, 2025
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12: 01 a.m., Eastern Time
June 12, 2025
Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
June 12, 2025
Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors
June 4, 2025
Shuttle Pharma Provides Corporate Update
May 15, 2025
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
May 8, 2025
Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
April 21, 2025
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
April 10, 2025
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
March 13, 2025
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
March 12, 2025
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
March 12, 2025
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
February 26, 2025
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
January 20, 2025
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 6, 2025
Decks in 2025
- Investor Presentation (April 2025)
Investor deck · 16 slides · April 2025